/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...
The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...
The company received a Complete Response Letter from the FDA regarding its prospective graft-versus-host disease therapy.
Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022...
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Chronic Low Back Pain due to Degenerative Disc Disease...
Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission...